0001209191-21-069963.txt : 20211216
0001209191-21-069963.hdr.sgml : 20211216
20211216163258
ACCESSION NUMBER: 0001209191-21-069963
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20211214
FILED AS OF DATE: 20211216
DATE AS OF CHANGE: 20211216
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Keuer Thomas A
CENTRAL INDEX KEY: 0001290482
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-22873
FILM NUMBER: 211498172
MAIL ADDRESS:
STREET 1: C/O ARCA BIOPHARMA, INC.
STREET 2: 10170 CHURCH RANCH WAY, STE 100
CITY: WESTMINSTER
STATE: CO
ZIP: 80021
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ARCA biopharma, Inc.
CENTRAL INDEX KEY: 0000907654
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 363855489
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10170 CHURCH RANCH WAY
STREET 2: SUITE 100
CITY: WESTMINSTER
STATE: CO
ZIP: 80021
BUSINESS PHONE: 7209402200
MAIL ADDRESS:
STREET 1: 10170 CHURCH RANCH WAY
STREET 2: SUITE 100
CITY: WESTMINSTER
STATE: CO
ZIP: 80021
FORMER COMPANY:
FORMER CONFORMED NAME: NUVELO INC
DATE OF NAME CHANGE: 20030203
FORMER COMPANY:
FORMER CONFORMED NAME: HYSEQ INC
DATE OF NAME CHANGE: 19970610
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-12-14
0
0000907654
ARCA biopharma, Inc.
ABIO
0001290482
Keuer Thomas A
10170 CHURCH RANCH WAY
SUITE 100
WESTMINSTER
CO
80021
0
1
0
0
Chief Operating Officer
Common Stock
730
D
Stock Option (right to buy)
2.29
2021-12-14
4
A
0
35000
0.00
A
2031-12-14
Common Stock
35000
35000
D
Grant to the Reporting Person of a stock option under the 2020 Equity Incentive Plan (the Plan), vesting in 36 equal monthly installments from the date of grant, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan prior to such time. In the event of a change in control of the Issuer, 50% of the unvested options shall become fully and immediately vested upon the closing date of such change in control, provided, however, that on the earlier of (i) the one-year anniversary of the closing date or (ii) involuntary termination, any options that remain unvested on such earlier date shall become fully and immediately vested.
/s/ C. Jeffrey Dekker, Attorney-in-Fact
2021-12-16
EX-24
2
poa.txt
POA DOCUMENT
LIMITED POWER OF ATTORNEY FOR
SECTION 16 REPORTING OBLIGATIONS
Know all by these presents, that the undersigned hereby constitutes and
appoints each of Michael R. Bristow, C. Jeffrey Dekker, Christopher D. Ozeroff,
Brent D. Fassett and Ryan Lewis, signing individually, the undersigned's true
and lawful attorneys-in fact and agents to:
(1) execute for and on behalf of the undersigned, in the undersigned's capacity
as an executive officer, member of the Board of Directors and/or greater than
10% stockholder of ARCA biopharma, Inc. (the "Company"), Forms 3, 4 and 5
(including any amendments thereto) in accordance with Section 16(a) of the
Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the rules
thereunder;
(2) do and perform any and all acts for and on behalf of the undersigned which
may be necessary or desirable to complete and execute any such Forms 3, 4 or 5
(including any amendments thereto) and timely file such forms with the
Securities and Exchange Commission and any stock exchange or similar authority;
and
(3) take any other action of any nature whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit to,
in the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in such
attorney-in-fact's discretion.
The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this power of attorney and the rights and powers herein
granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in
serving in such capacity at the request of the undersigned, are not assuming,
nor is the Company assuming, any of the undersigned's responsibilities to comply
with Section 16 of the Exchange Act.
This Power of Attorney shall remain in full force and effect until the earliest
to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5
with respect to the undersigned's holdings of and transactions in securities
issued by the Company, (b) revocation by the undersigned in a signed writing
delivered to the foregoing attorneys-in-fact, or (c) as to any attorney-in-fact
individually, until such attorney-in-fact is no longer employed by the Company
or employed by or a partner at Cooley LLP, as applicable.
The undersigned has caused this Power of Attorney to be executed as of the 13th
of May, 2021.
/s/ Thomas A. Keuer
________________________________
Thomas A. Keuer